SS-31, a mitochondria-targeting tetrapeptide also known as elamipretide (previously designated MTP-131 or Bendavia), has been investigated across a set of conditions that share mitochondrial dysfunction rather than a single organ system. The honest bottom line is that as of September 2025 the compound holds one FDA accelerated approval, for Barth syndrome under the brand FORZINITY, while every other use remains investigational and several late-stage trials have returned mixed or negative results. Being studied for a condition documents a tested hypothesis, not a proven benefit.
SS-31, also known as elamipretide, has been studied across mitochondrial myopathy, Barth syndrome, heart failure, ischemia-reperfusion injury, dry age-related macular degeneration, and kidney disease, and as of September 2025 holds FDA approval only for Barth syndrome (as FORZINITY) while remaining investigational for every other use.
Primary mitochondrial myopathy became the flagship SS-31 indication because muscle tissue depends heavily on oxidative phosphorylation, which made it a logical test bed for a peptide aimed at the electron transport chain. The MMPOWER trial series enrolled adults with genetically confirmed disease and measured objective endpoints, chiefly the six-minute walk distance alongside patient-reported fatigue. What the record shows is a program that opened with encouraging dose-ranging signals but whose pivotal MMPOWER-3 trial missed its primary endpoints.
The pivotal MMPOWER-3 trial in primary mitochondrial myopathy showed no statistically significant improvement in six-minute walk distance or the primary fatigue measure over placebo at 24 weeks.
The heart draws the vast majority of its ATP from mitochondrial oxidative phosphorylation, which is why cardiac medicine became an early proving ground for SS-31, pursued across two distinct scenarios. Acute ischemia-reperfusion injury was tested in the EMBRACE-STEMI trial, in patients undergoing angioplasty for a first heart attack, and that trial did not significantly reduce infarct size versus placebo. Chronic heart failure with reduced ejection fraction drew smaller studies of cardiac function, against a recurring translational gap in which animal-model protection failed to reproduce as human outcomes.
| Criteria | Acute ischemia-reperfusion | Chronic heart failure |
|---|---|---|
| Setting | Angioplasty after first heart attack | Reduced ejection fraction |
| Trial | EMBRACE-STEMI | Smaller function studies |
| Endpoint | Infarct size (enzymes, imaging) | Cardiac function, remodeling |
| Result | No significant reduction vs placebo | Suggestive, not confirmatory |
In the EMBRACE-STEMI trial, SS-31 given to first-heart-attack patients undergoing angioplasty did not show a significant reduction in infarct size versus placebo.
Barth syndrome offers the tightest mechanistic fit of any SS-31 indication, because the disease stems from TAZ gene mutations that disrupt cardiolipin, the exact inner-membrane phospholipid the peptide binds. The TAZPOWER trial studied adolescents and adults with genetically confirmed disease, and its randomized crossover portion did not meet primary endpoints within a short window, while the longer open-label extension reported functional gains that grew over many months. That extension pattern, together with the ultra-rare population, informed the FDA's September 2025 accelerated approval of elamipretide as FORZINITY to improve muscle strength in Barth syndrome.
| Trial phase | Randomized crossover | Open-label extension |
|---|---|---|
| Duration | Short crossover window | Many months |
| Primary endpoints | Not met | Functional gains reported |
| Measures | Six-minute walk, muscle strength | Walk distance, strength |
The randomized crossover portion of TAZPOWER did not meet its primary endpoints, but the open-label extension reported growing functional gains, and elamipretide received FDA accelerated approval for Barth syndrome in September 2025.
The kidney is densely packed with mitochondria, especially the proximal tubule cells that carry out energy-intensive reabsorption, so ischemic or toxic damage translates quickly into lost filtration, which frames the interest in SS-31 as a renal protectant. Most renal work has centered on acute kidney injury following restricted blood flow or exposure to nephrotoxic agents such as radiocontrast dye, with a preclinical rationale extending to diabetic and chronic kidney disease. Compared with the cardiac and myopathy programs, the renal effort has stayed earlier in stage, resting more on animal and mechanistic support than on large completed human outcome trials.
The renal work on SS-31 has centered on acute kidney injury and remains earlier in stage, resting more heavily on preclinical and mechanistic support than on large completed human outcome trials.
Calling SS-31 investigational for most of these conditions is a precise regulatory statement, not a hedge. One exception now exists: the September 2025 FDA accelerated approval of elamipretide as FORZINITY for muscle strength in Barth syndrome, which makes it an approved prescription drug for that single indication. For every other disease no regulator has concluded the benefits outweigh the risks, and rare-disease designations such as orphan drug or fast-track status are procedural accommodations, not certifications of efficacy or safety.
SS-31 is investigational and not approved for any condition except Barth syndrome, for which elamipretide received FDA accelerated approval as FORZINITY in September 2025; rare-disease designations such as orphan or fast-track status are procedural, not proof of efficacy.
Read honestly, the trial record documents a well-tolerated compound that has struggled to prove efficacy on the endpoints that matter most. Its three most rigorous late-stage tests all missed their primary endpoints, so no indication can currently claim a clean confirmatory positive result apart from the Barth-syndrome approval that rested partly on open-label data. Scattered secondary signals and a strong safety profile, dominated by injection-site reactions, are part of why development has persisted despite the misses.
| Trial | Indication | Primary endpoint result |
|---|---|---|
| MMPOWER-3 | Mitochondrial myopathy | Not met |
| TAZPOWER (randomized) | Barth syndrome | Not met |
| EMBRACE-STEMI | Ischemia-reperfusion injury | No infarct-size reduction |
The three most rigorous late-stage SS-31 trials, MMPOWER-3, the randomized portion of TAZPOWER, and EMBRACE-STEMI, all missed their primary endpoints, while the safety profile stayed favorable with injection-site reactions as the most common complaint.
Beyond the flagship cardiac, myopathy, retinal, Barth, and renal programs, SS-31 has drawn preclinical and exploratory interest in a longer list of conditions united only by a mitochondrial angle. Age-related muscle decline, neurodegenerative diseases such as Parkinson-type conditions, and various metabolic and fibrotic injuries have generated laboratory-level curiosity in aging animal models and cell culture. These directions rest on the least predictive tier of evidence and sit against a backdrop in which the compound's most advanced and best-funded human trials have repeatedly fallen short.
The emerging SS-31 indications, including sarcopenia, neurodegenerative disease, and metabolic and fibrotic injury, rest largely on cell-culture and animal data, the least predictive tier of evidence, and should be treated as research hypotheses rather than validated uses.
Educational use only. This article describes what the published scientific and clinical literature reports about SS-31. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
